INTERIM REPORT TABLE OF CONTENTS I. INTERIM MANAGEMENT REPORT 1 II. INTERIM CONDENSED UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS MDXHEALTH SA 3 1. CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER C

This Interim Report contains forward-looking

statements and estimates with respect to the anticipated future performance of MDxHealth SA and its wholly-owned subsidiaries (hereinafter

"MDxHealth" or the "Company") and the market in which it operates. Such statements and estimates are based on

assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove

to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn

out to be materially different. Important factors that could cause actual results, conditions and events to differ materially from those

indicated in the forward-looking statements include, among others, the following: the Company's plans relating to commercializing

its tests and related diagnostic products and services (collectively "tests", "testing solutions" or "solutions")

and the rate and degree of market acceptance of its solutions; the size of the market opportunity for the Company's Confirm mdx,

Select mdx, Resolve mdx, Monitor mdx and Genomic Prostate Score ("GPS") tests and other future tests and solutions it may

commercialize or develop; the acceptance of the Company's testing solutions by healthcare providers; the willingness of health

insurance companies and other payers to cover the Company's testing solutions and adequately reimburse the Company for such solutions;

the Company's plans relating to the further development of testing solutions; existing regulations and regulatory developments

in the United States, Europe and other jurisdictions; the Company's ability to obtain and maintain regulatory approvals and comply

with applicable regulations; timing, progress and results of the Company's research and development programs; the period over which

the Company estimates its existing cash will be sufficient to fund future operating expenses and capital expenditure requirements; our

ability to remain in compliance with financial covenants made to and make scheduled payments to our creditors; the Company's ability

to attract and retain qualified employees and key personnel; the scope of protection the Company is able to establish and maintain for

intellectual property rights covering its testing solutions and technology; the Company's ability to operate its business without

infringing the intellectual property rights and proprietary technology of third parties; the possibility that the anticipated benefits

from the Company's business acquisitions will not be realized in full or at all or may take longer to realize than expected; costs

associated with defending intellectual property infringement, product liability and other claims; and uncertainties associated with global

macroeconomic conditions. The risks included above are not exhaustive. Other important risks and uncertainties are described in the Risk

Factors section of the 2023 Annual Report on Form 20-F and under the heading "Principal risks related to the business activities"

in "Section I. Interim Management Report" below. You are further cautioned not to place undue reliance upon any such forward-looking

statements, which speak only as of the date made. MDxHealth expressly disclaims any obligation to update any such forward-looking statements

in this Interim Report to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances

on which any such statement is based unless required by law or regulation. This Interim Report does not constitute an offer or invitation

for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold

within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom,

and in accordance with any applicable U.S. securities laws.

I. INTERIM MANAGEMENT REPORT

Key non-audited financials, as of June 30,

Key unaudited consolidated figures for the six

months ended June 30, 2024 and 2023 (thousands of U.S. dollars, except per share data):

Revenue increased 34% to $42.0 million compared

to $31.4 million for the prior year.

Gross profit increased 36% to $25.3 million compared

to $18.7 million for the prior year. Gross margins were 60.4% as compared to 59.5% for the prior year, an improvement of 90 basis points.

Operating loss decreased 15% to $14.0 million

compared to $16.5 million for the prior year, driven by higher revenues and gross profit.

Net loss decreased 10% to $20.0 million compared

to $22.3 million for the prior year, primarily driven by the factors mentioned above.

Justification to continue using the accounting

rules on the basis of going concern

The Company has experienced net losses and significant

cash used in operating activities since its inception in 2003, and as of and for the period ended June 30, 2024, had an accumulated deficit

of $351.5 million, a net loss of $20.0 million, and net cash used in operating activities of $9.8 million. Management expects the Company

to continue to incur net losses and have significant cash outflows for at least the next twelve months.

While these conditions, among others, could raise

substantial doubt about its ability to continue as a going concern, these consolidated financial statements have been prepared assuming

that the Company will continue as a going concern. This basis of accounting contemplates the recovery of its assets and the satisfaction

of liabilities in the normal course of business. A successful transition to attaining profitable operations is dependent upon achieving

a level of positive cash flows adequate to support the Company's cost structure.

As of June 30, 2024, the Company had cash and

cash equivalents of $21.3 million. Taking into account the above financial situation and on the basis of the most recent business plan,

including the Company's expected ability to access additional cash through debt, equity, or other means, the Company believes that

it has sufficient cash to be able to continue its operations for at least the next twelve months from the date of issuance of these financial

statements, and accordingly has prepared the consolidated financial statements assuming that it will continue as a going concern. This

assessment is based on forecasts and projections within management's most recent business plan as well as the Company's expected

ability to maintain adequate levels of cash as required by certain financial covenants present in the new OrbiMed Loan Facility (described

in Note 9), and to access additional cash through debt, equity or other means, for which at this moment, a material uncertainty exists

that casts substantial doubt on the Company's ability to continue as a going concern.

Principal risks related to the business

MDxHealth operates in a rapidly changing environment

that involves a number of risks that could materially affect its business, financial condition or future results, some of which are beyond

the Company's control. In addition to the other information set forth in this section and elsewhere in this Interim Report, the

risks and uncertainties that the Company believes are most important for you to consider have been outlined in the 2023 Annual Report

on Form 20-F, which is available on the Securities and Exchange Commission's website as well as the Company's website at www.mdxhealth.com/investors/financials.

Our credit facility contains restrictions

that limit our flexibility in operating our business, and if we fail to comply with the covenants and other obligations under our credit

facility, the lenders may be able to accelerate amounts owed under the facility and may foreclose upon the assets securing our obligations.

1, 2024, the Company entered into a $100 million Credit Agreement (the "Credit Agreement") with certain funds managed by

OrbiMed Advisors LLC ("OrbiMed"). The Company and OrbiMed entered into amendments to the Credit Agreement in July and

August 2024, pursuant to which certain financial covenants were amended and certain amendment fees became payable. The Credit

Agreement provides for a five-year senior secured credit facility in an aggregate principal amount of up to $100 million (the

"Loan Facility"), of which (i) $55 million was advanced on May 1, 2024, (ii) $25 million will be made available, at the Company's discretion, on or prior to March 31, 2025, subject to certain net revenue

requirements and other customary conditions, and (iii) $20 million will be made available, at the Company's discretion, on or prior

to March 31, 2026, subject to certain net revenue requirements and other customary conditions. Subsequent amendments to the Credit Agreement

added a minimum liquidity level condition to the $25 million additional loan draw. All obligations under the credit agreement are secured

by substantially all of the Company's assets, including intellectual property rights.

The Company is subject to a number of

affirmative and restrictive covenants pursuant to the Credit Agreement, which limit or restrict its ability to (subject to certain

qualifications and exceptions): create liens and encumbrances; incur additional indebtedness; merge, dissolve, liquidate or

consolidate; make acquisitions, investments, advances or loans; dispose of or transfer assets; pay dividends or make other payments

in respect of their capital stock; amend certain material documents; redeem or repurchase certain debt; engage in certain

transactions with affiliates; enter into certain restrictive agreements; and engage in certain other activities customary for a

senior secured credit facility. In addition, if, for any quarter beginning on June 30, 2025 and until the maturity date of the Loan

Facility, the Company's net revenue does not meet certain minimum amounts, then, subject to certain cure rights specified in

the Credit Agreement, MDxHealth shall be required to begin to repay the outstanding principal amount of the Loan Facility in equal

monthly installments, together with accrued interest on the principal repaid and a repayment premium and other fees, until the

maturity date of the Loan Facility. In addition, the Company will be required to maintain certain levels of unrestricted cash and

cash equivalents during various time periods, including monthly assessments thereof, initially at a minimum level of $20 million and

subsequently reducing to a $5 million minimum level following the achievement of certain milestones, as further described in the

Credit Agreement filed as exhibit 4.1 to Form 6-K, dated May 1, 2024. Subsequent amendments to the Credit Agreement, filed as

exhibits 4.1 and 4.2 to Form 6-K dated August 21, 2024, have temporarily reduced the initial minimum level of unrestricted cash and

cash equivalents to $12.5 million until the end of the current calendar year.

The Company's obligations under the Credit